Neoantigen Identification
Accurate and comprehensive neoantigen detection, characterization, and prioritization for personalized therapeutics
Neoantigen Identification
Mutations in protein coding genes of cancer cells are a source of potential neoantigens that the immune system can target. Characterization of expressed neoantigens has contributed to development of personalized cancer therapeutics. NGS has enabled the predictive selection of novel tumor antigens that can be applied to elicit a tumor-specific response.
Admera Health characterizes DNA and RNA across all ~20,000 genes in a tumor and matched normal sample configuration by exome sequencing and transcriptome sequencing. As a result, an extensive evaluation of candidate neoantigens derived from SNVs, indels, and/or fusions are provided. Based on proprietary bioinformatics analysis method, Admera Health is able to provide accurate and comprehensive neoantigen detection, characterization, and prioritization.
Neoantigen Identification Advances Personalized Therapeutics
Biomarker discovery to monitor treatment response
Immuno-therapy
efficacy prediction
Personalized
Cancer Vaccine
Admera Health’s Comprehensive Solution
Seamless and efficient research journey from start to finish
Our group of multidisciplinary experts have extensive experience in discovery of new preclinical biomarkers for research and analyzing known clinical biomarkers.
Neoantigen Solutions at Admera Health
High quality data for DNA-seq or RNA-seq: CLIA-certified lab with well established NGS platforms
HLA Typing: Validated pipeline for accurate typing based on both DNA-seq and RNA-seq
Correct peptide determination: proprietary somatic mutation determination methods including frameshift, Indel-derived and out-of-frame fusion-derived peptides
Neoantigen candidate prioritization: Integrated DNA-seq and RNA-seq analysis for most accurate neoantigen prioritization, including binding affinity, variant allele frequency, immunogenicity, gene expression, peptide toxicity, and several other considerations
*Listed solutions for human samples, please inquire for alternative sample origins
Neoantigen Workflow at Admera Health
A. Sample preparation, starting from dual isolation of RNA and DNA from FFPE sample. B. Samples undergo library preparation through Admera Health’s optimized whole exome sequencing and whole transcriptomic pipelines C. High-throughput sequencing is performed on Illumina NovaSeq X Plus platform. D. Following sequencing, Admera Health team performs comprehensive bioinformatic analysis to evaluate and identify neoantigen candidates which includes variant detection and annotation using multiple tools, HLA-typing (DNA-seq and RNA-seq), neoantigen detection and filtering (including expression), neoantigen stability prediction, and cleavage site prediction. Additionally, Admera offers insight in vaccine design by introducing a choice of spacer to remedy the issue of junctional peptide
Neoantigen Deliverables
Identification and ranking of neoantigens
Peptide sequence optimization for neoantigen expression
Allelic fraction and gene-
and variant-level expression
Phasing for allele-specific expression determination
Get the Most out of Your Neoantigen Project
Maximize your project’s potential with advanced data analysis solutions. Our team of expert bioinformaticians curate pipelines tailored to your project’s experimental design.
See our sample submission guideline for sample preparation, packing, and shipping instructions.
